Gilead GS-840 (adefovir dipivoxil) for HIV therapy on track for 1998 NDA, company tells Alex. Brown.
Executive Summary
GILEAD SCIENCES HOPING TO FILE 1998 NDA FOR HIV TREATMENT GS-840 (adefovir dipivoxil), Gilead Senior VP for Drug Development Howard Jaffe, MD, told an Alex. Brown analysts meeting in Baltimore. If a pivotal Phase II/III study underway "is positive, as we expect it to be, we anticipate filing an NDA in the first half of next year," Jaffe announced. The pivotal study, for which Gilead has completed accrual of 400 patients, will be completed this year, he said.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth